Scribe Therapeutics Inc. (SCTX)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Benjamin L. Oakes Ph.D.
|
Co-Founder, President, CEO & Chairman | 574.98k | -- | 1989 |
|
Mr. David L. Parrot M.B.A.
|
CFO & Treasurer | 475.83k | -- | 1969 |
|
Dr. Svetlana Lucas Ph.D.
|
Chief Operating Officer | 466.98k | -- | 1972 |
|
Dr. Jennifer A. Doudna Ph.D.
|
Co-Founder & Scientific Advisor | -- | -- | 1964 |
|
Mr. Brett T. Staahl Ph.D.
|
Co-Founder & VP of External Innovation | -- | -- | -- |
|
Mr. David F. Savage Ph.D.
|
Co-Founder & Scientific Advisor | -- | -- | -- |
|
Mr. Richard Hector J.D., Ph.D.
|
Head of Intellectual Property | -- | -- | -- |
|
Ms. Chitra Sharma M.S.
|
Senior Vice President of Development | -- | -- | -- |
|
Mr. Sunny Mok M.B.A., Ph.D.
|
Senior Vice President of Operations | -- | -- | -- |
|
Stephen V. Thau
|
Secretary | -- | -- | -- |
Scribe Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 82
Description
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.
Corporate Governance
Upcoming Events
November 11, 2026 at 9:00 PM UTC
Scribe Therapeutics Inc. Earnings Date
